Call us : USA : 1-631-381-2994; Europe : 44-207-097-1828
Mail us : info@creative-biolabs.com
Creative Biolabs Bispecific Antibody Blog

Menu

Skip to content
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News

Monthly Archives: November 2018

Research and Development of Blinatumomab in B Cell Malignant Tumor

November 22, 2018Bispecific Antibody Clinic, Bispecific Antibody ResearchBispecific Antibody, Bispecific T Cell Engager, Blinatumomabbiobsab

Blinatumomab is a CD19/CD3 bispecific antibody that is the first bispecific T cell engager (BiTE) and the first CD19-specific antibody approved by the U.S. Food and Drug Administration (FDA). As an immunotherapyRead More…

Categories

  • Bispecific Antibody Clinic
  • Bispecific Antibody Research
  • News

Recent Posts

  • Bispecific Antibodies Targeting Dual Tumor-associated Antigens
  • Difficulties and Prospects in the Research and Development of Bispecific Antibodies
  • Current Status of Research and Development of Multispecific Antibodies
  • How to Develop A Qualified Bispecific Antibody
  • Amgen Bispecific Antibody BLINCYTO® (blinatumomab) Significantly Prolongs the Overall Survival Time of Patients with Leukemia

Archives

  • December 2020
  • October 2020
  • August 2020
  • June 2019
  • April 2019
  • March 2019
  • February 2019
  • December 2018
  • November 2018
  • October 2018

Contact Us

USA:
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: info@creative-biolabs.com
Europe:
Tel: 44-207-097-1828
Copyright © Creative Biolabs Bispecific Antibody Blog
Powered by WordPress , Designed and Developed by templatesnext
MENU
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News